Bryn Mawr Trust CO Exelixis, Inc. Transaction History
Bryn Mawr Trust CO
- $5.44 Billion
- Q4 2024
A detailed history of Bryn Mawr Trust CO transactions in Exelixis, Inc. stock. As of the latest transaction made, Bryn Mawr Trust CO holds 794 shares of EXEL stock, worth $26,321. This represents 0.0% of its overall portfolio holdings.
Number of Shares
794
Previous 704
12.78%
Holding current value
$26,321
Previous $18,000
44.44%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding EXEL
# of Institutions
520Shares Held
244MCall Options Held
2.84MPut Options Held
2.29M-
Black Rock Inc. New York, NY33.5MShares$1.11 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA29.3MShares$972 Million0.01% of portfolio
-
Farallon Capital Management LLC San Francisco, CA25.4MShares$842 Million3.31% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny15.4MShares$509 Million0.63% of portfolio
-
State Street Corp Boston, MA11.4MShares$379 Million0.01% of portfolio
About EXELIXIS, INC.
- Ticker EXEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 321,832,000
- Market Cap $10.7B
- Description
- Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...